BriaCell Therapeutics Corp., a biotechnology company focused on transforming cancer treatment, has been awarded a $2 million research grant from the National Cancer Institute to support the manufacturing of Bria-PROS+, the company’s off-the-shelf immunotherapy for prostate cancer, and help launch an upcoming clinical trial.
According to a press release, Bria-PROS+ is designed for patients with metastatic hormone-sensitive prostate cancer, a condition with limited treatment options.
“The Bria-OTS+ platform was designed to overcome the complexity, cost and delays of traditional personalized cancer treatments. We believe it will constitute a significant advancement in personalized cancer care,” BriaCell’s Miguel Lopez-Lago said in a statement.
